BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: Hsp70-Bim interaction protected BCR-ABL-independent TKI-resistant CML cells from apoptosis, and, thus, treatment with compound 5a can overcome the resistance of a highly problematic CML type.